BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

962 related articles for article (PubMed ID: 33485385)

  • 1. Comprehensive metabolic profiling of Parkinson's disease by liquid chromatography-mass spectrometry.
    Shao Y; Li T; Liu Z; Wang X; Xu X; Li S; Xu G; Le W
    Mol Neurodegener; 2021 Jan; 16(1):4. PubMed ID: 33485385
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LC-MS-based urinary metabolite signatures in idiopathic Parkinson's disease.
    Luan H; Liu LF; Meng N; Tang Z; Chua KK; Chen LL; Song JX; Mok VC; Xie LX; Li M; Cai Z
    J Proteome Res; 2015 Jan; 14(1):467-78. PubMed ID: 25271123
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive urinary metabolomic profiling and identification of potential noninvasive marker for idiopathic Parkinson's disease.
    Luan H; Liu LF; Tang Z; Zhang M; Chua KK; Song JX; Mok VC; Li M; Cai Z
    Sci Rep; 2015 Sep; 5():13888. PubMed ID: 26365159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Potential biomarkers of Parkinson's disease revealed by plasma metabolic profiling.
    Zhao H; Wang C; Zhao N; Li W; Yang Z; Liu X; Le W; Zhang X
    J Chromatogr B Analyt Technol Biomed Life Sci; 2018 Apr; 1081-1082():101-108. PubMed ID: 29518718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Untargeted serum metabolomics reveals novel metabolite associations and disruptions in amino acid and lipid metabolism in Parkinson's disease.
    Paul KC; Zhang K; Walker DI; Sinsheimer J; Yu Y; Kusters C; Del Rosario I; Folle AD; Keener AM; Bronstein J; Jones DP; Ritz B
    Mol Neurodegener; 2023 Dec; 18(1):100. PubMed ID: 38115046
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct metabolomic signature in cerebrospinal fluid in early parkinson's disease.
    Trezzi JP; Galozzi S; Jaeger C; Barkovits K; Brockmann K; Maetzler W; Berg D; Marcus K; Betsou F; Hiller K; Mollenhauer B
    Mov Disord; 2017 Oct; 32(10):1401-1408. PubMed ID: 28843022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profiling novel metabolic biomarkers for Parkinson's disease using in-depth metabolomic analysis.
    Han W; Sapkota S; Camicioli R; Dixon RA; Li L
    Mov Disord; 2017 Dec; 32(12):1720-1728. PubMed ID: 28880465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated biomarker for type 2 diabetes mellitus and impaired fasting glucose based on metabolomics analysis using ultra-high performance liquid chromatography quadrupole-Orbitrap high-resolution accurate mass spectrometry.
    Long J; Liu L; Jia Q; Yang Z; Sun Z; Yan C; Yan D
    Rapid Commun Mass Spectrom; 2020 Jun; 34(12):e8779. PubMed ID: 32159245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metabolic Profiling of CSF from People Suffering from Sporadic and LRRK2 Parkinson's Disease: A Pilot Study.
    Yilmaz A; Ugur Z; Ustun I; Akyol S; Bahado-Singh RO; Maddens M; Aasly JO; Graham SF
    Cells; 2020 Oct; 9(11):. PubMed ID: 33142859
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative metabolomics of saliva using proton NMR spectroscopy in patients with Parkinson's disease and healthy controls.
    Kumari S; Goyal V; Kumaran SS; Dwivedi SN; Srivastava A; Jagannathan NR
    Neurol Sci; 2020 May; 41(5):1201-1210. PubMed ID: 31897951
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A metabolomic signature of treated and drug-naïve patients with Parkinson's disease: a pilot study.
    Troisi J; Landolfi A; Vitale C; Longo K; Cozzolino A; Squillante M; Savanelli MC; Barone P; Amboni M
    Metabolomics; 2019 Jun; 15(6):90. PubMed ID: 31183578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recent advances and perspectives of metabolomics-based investigations in Parkinson's disease.
    Shao Y; Le W
    Mol Neurodegener; 2019 Jan; 14(1):3. PubMed ID: 30634989
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Integrated metabolomic profiling of hepatocellular carcinoma in hepatitis C cirrhosis through GC/MS and UPLC/MS-MS.
    Fitian AI; Nelson DR; Liu C; Xu Y; Ararat M; Cabrera R
    Liver Int; 2014 Oct; 34(9):1428-44. PubMed ID: 24661807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolite and peptide levels in plasma and CSF differentiating healthy controls from patients with newly diagnosed Parkinson's disease.
    Trupp M; Jonsson P; Ohrfelt A; Zetterberg H; Obudulu O; Malm L; Wuolikainen A; Linder J; Moritz T; Blennow K; Antti H; Forsgren L
    J Parkinsons Dis; 2014; 4(3):549-60. PubMed ID: 24927756
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnostic metabolomic profiling of Parkinson's disease biospecimens.
    LeWitt PA; Li J; Wu KH; Lu M
    Neurobiol Dis; 2023 Feb; 177():105962. PubMed ID: 36563791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lipid metabolic dysregulation is involved in Parkinson's disease dementia.
    Dong MX; Wei YD; Hu L
    Metab Brain Dis; 2021 Mar; 36(3):463-470. PubMed ID: 33433787
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breast cancer detection using targeted plasma metabolomics.
    Jasbi P; Wang D; Cheng SL; Fei Q; Cui JY; Liu L; Wei Y; Raftery D; Gu H
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jan; 1105():26-37. PubMed ID: 30562627
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential metabolomic biomarkers for reliable diagnosis of Behcet's disease using gas chromatography/ time-of-flight-mass spectrometry.
    Ahn JK; Kim J; Hwang J; Song J; Kim KH; Cha HS
    Joint Bone Spine; 2018 May; 85(3):337-343. PubMed ID: 28549946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolomics Fingerprint Induced by the Intranigral Inoculation of Exogenous Human Alpha-Synuclein Oligomers in a Rat Model of Parkinson's Disease.
    Murgia F; Atzori L; Carboni E; Santoru ML; Hendren A; Pisanu A; Caboni P; Boi L; Fusco G; Carta AR
    Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32937957
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 49.